IDH2 and central nervous system cancer: The hallmark of the new WHO classification with its molecular distinction in the first place between IDH-wild type and IDH-mutant gliomas, and the following classification of all IDH wild type tumors as grade IV may lead to a shift from historic low grade (WHO II and III) to GBM grade IV, in our cohort.